Mark Pruzanski, President & CEO at INTERCEPT PHARMACEUTICALS, INC. (ICPT), sold 2,397 shares at $125.00 ($297K) on 2019-12-31, disclosed to the SEC on 2020-01-03.
Scheduled sale ($297k) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $123.92 | 1,131 | $140K | 47.2% |
| 2 | $125.00 | 100 | $13K | 4.2% |
| 3 | $123.92 | 1,166 | $144K | 48.6% |
| Total | $123.97 avg | 2,397 | $297K | 100% |
| Filing → |
| ICPT | SELL | 2018-11-16 | $9.1M | — | Filing → |
| ICPT | BUY | 2018-04-09 | $500K | — | Filing → |
| ICPT | SELL | 2017-10-04 | $180K | — | Filing → |